SFJ Pharmaceuticals X Ltd. is countersuing bankrupt PhaseBio Pharmaceuticals Inc., seeking court recognition of its equity stake in their co-development program for the antibody drug bentracimab.
SFJ, which is backed by the Blackstone Group, also asked the Delaware bankruptcy court to recognize that it owns the data generated by clinical trials of the drug it funded.
The lawsuit could stymie PhaseBio’s efforts to sell the drug to raise proceeds for paying back its creditors, PhaseBio says.
PhaseBio’s sued SFJ Oct. 31, asking the bankruptcy court to confirm its ownership of the drug’s clinical trial and related data.
PhaseBio also is ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.